Wells Fargo Maintains Equal-Weight on RxSight, Raises Price Target to $27
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Larry Biegelsen maintains an Equal-Weight rating on RxSight (NASDAQ:RXST) and raises the price target from $17 to $27.
June 05, 2023 | 11:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo maintains an Equal-Weight rating on RxSight and raises the price target from $17 to $27.
The price target increase from $17 to $27 by Wells Fargo analyst Larry Biegelsen indicates a positive outlook for RxSight's stock. This news is likely to have a short-term positive impact on the stock price as it shows increased confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100